Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Rocket Pharmaceuticals (RCKT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK) and Rocket Pharmaceuticals (RCKT) with bullish sentiments.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cytokinetics (CYTK)
In a report issued on May 5, Tessa Romero from J.P. Morgan maintained a Buy rating on Cytokinetics, with a price target of $92.00. The company’s shares closed last Friday at $76.91.
According to TipRanks.com, Romero is a 5-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $99.65, implying a 33.7% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $82.00 price target.
See the top stocks recommended by analysts >>
Rocket Pharmaceuticals (RCKT)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Rocket Pharmaceuticals, with a price target of $11.00. The company’s shares closed last Friday at $3.63.
According to TipRanks.com, Livshits is a 4-star analyst with an average return of
Rocket Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $9.67, a 156.5% upside from current levels. In a report issued on April 28, LifeSci Capital also maintained a Buy rating on the stock with a $12.00 price target.
Read More on CYTK:
